Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2012 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2012 - 2020
Diagnostics (Dx) Revenue	10.73B	10.14B	Log In	Log In	Log In	Upgrade
Biopharma Laboratory Services (BLS) Revenue	3.07B	2.92B	Log In	Log In	Log In	Upgrade
Revenue (Other)	-41.10M	-58.00M	Log In	Log In	Log In	Upgrade
Revenue (Total)	13.77B	13.01B	Log In	Log In	Log In	Upgrade

EBIT

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2012 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2012 - 2020
Diagnostics (Dx) Operating Earnings	1.72B	1.61B	Log In	Log In	Log In	Upgrade
Biopharma Laboratory Services (BLS) Operating Earnings	493.20M	458.90M	Log In	Log In	Log In	Upgrade
Operating Income (Other)	-879.80M	-978.50M	Log In	Log In	Log In	Upgrade
Operating Income (Total)	1.33B	1.09B	Log In	Log In	Log In	Upgrade

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2012 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2012 - 2020
North America % Total Revenue	-	87.00%	Log In	Log In	Log In	Upgrade
Europe % Total Revenue	-	9.00%	Log In	Log In	Log In	Upgrade
Other Geography % Total Revenue	-	4.00%	Log In	Log In	Log In	Upgrade
Organic Revenue Growth	-	3.90%	Log In	Log In	Log In	Upgrade

Updated Sep 30, 2025. Data Source: Fiscal.ai.